Day One Biopharmaceuticals Completes Acquisition of Mersana Therapeutics, Expanding Oncology Pipeline
DAWN sits 53% above its 52-week low of $5.635.
Summary
Day One Biopharmaceuticals has completed its acquisition of Mersana Therapeutics for $128.8 million in cash plus contingent value rights, significantly expanding its clinical pipeline with the addition of emiltatug ledadotin (Emi-Le), a novel antibody drug conjugate.
Key Events · M&A and Partnerships · DAWN
-
Acquisition Completion
Day One Biopharmaceuticals completed the acquisition of Mersana Therapeutics, Inc. on January 6, 2026, making Mersana a direct wholly-owned subsidiary.
-
Transaction Value
The acquisition involved an upfront cash payment of approximately $128.8 million, funded from Day One's available cash on hand.
-
Contingent Value Rights (CVRs)
Former Mersana shareholders will receive one non-tradable CVR per share, offering potential payments up to an aggregate of $30.25 per CVR upon the achievement of nine specific development and commercial milestones for Emi-Le, with deadlines extending through 2037.
-
Pipeline Expansion
The acquisition adds emiltatug ledadotin (Emi-Le), a clinical-stage antibody drug conjugate targeting B7-H4 for rare cancers, to Day One's pipeline, expanding its focus into adult oncology.
Analysis · DAWN · Life Sciences
This acquisition is a highly significant strategic move for Day One Biopharmaceuticals, representing a substantial investment to broaden its oncology pipeline. The addition of Emi-Le, a clinical-stage antibody drug conjugate targeting B7-H4 for rare cancers like adenoid cystic carcinoma, diversifies Day One's therapeutic focus beyond pediatric low-grade glioma. The upfront cash payment of $128.8 million, funded from available cash, is a material use of capital. The contingent value rights (CVRs) offer former Mersana shareholders potential future payments up to $30.25 per share upon the achievement of nine specific development and commercial milestones for Emi-Le, extending through 2037. While the CVRs introduce future upside, they also carry inherent uncertainty regarding milestone achievement. Investors should monitor the progress of Emi-Le's clinical development and the integration of Mersana's assets into Day One's operations.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DAWN was trading at $8.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $877.9M. The 52-week trading range was $5.64 to $13.53. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.